Author:
Loizaga-Iriarte A.,Rodriguez-Antolin A.,Miñana B.,Lacasa-Viscasillas I.,Senarriaga-Ruiz de la Illa N.,Cozar-Olmo J.M.,Unda-Urzaiz M.
Reference14 articles.
1. NCCN Clinical practice guidelines in oncology: Prostate cancer. Version 2.2016. [consultado 10 Abr 2016]. Disponible en: www.nccn.org
2. EAU Guidelines 2016. [consultado 10 Abr 2016]. Disponible en: http://uroweb.org/guideline/prostate-cancer/
3. AUA castration-resistant prostate cancer guideline. [consultado 10 Abr 2016]. Disponible en: http://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm
4. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A meta-analysis;Shen;Skeletal Radiol,2014
5. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献